Zobor D, Strasser T, Zobor G, Schober F, Messias A, Strauss O, et al. (April 2015). "Ophthalmological assessment of cannabis-induced persisting perception disorder: is there a direct retinal effect?". Documenta Ophthalmologica. Advances in Ophthalmology. 130 (2): 121–130. doi:10.1007/s10633-015-9481-2. PMID25612939. S2CID9684212.
Halpern JH, Lerner AG, Passie T (2016). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 333–360. doi:10.1007/7854_2016_457. ISBN978-3-662-55878-2. PMID27822679.
Halpern JH, Pope HG (March 2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–119. doi:10.1016/s0376-8716(02)00306-x. PMID12609692.
Sandison RA, Spencer AM, Whitelaw JD (April 1954). "The therapeutic value of lysergic acid diethylamide in mental illness". The Journal of Mental Science. 100 (419): 491–507. doi:10.1192/bjp.100.419.491. PMID13175011.
Robbins E, Frosch WA, Stern M (September 1967). "Further observations on untoward reactions to LSD". The American Journal of Psychiatry. 124 (3): 393–395. doi:10.1176/ajp.124.3.393. PMID6066637.
Horowitz MJ (October 1969). "Flashbacks: recurrent intrusive images after the use of LSD". The American Journal of Psychiatry. 126 (4): 565–569. doi:10.1176/ajp.126.4.565. PMID5806803.
Passie T, Schneider U, Borsutzky M, Breyer R, Emrich HM, Bandelow B, Schmid-Ott G (2013). "Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm". Psychology, Health & Medicine. 18 (3): 363–374. doi:10.1080/13548506.2012.722649. PMID23186162. S2CID39115198.
Simeon D, Kozin DS, Segal K, Lerch B, Dujour R, Giesbrecht T (January 2008). "De-constructing depersonalization: further evidence for symptom clusters". Psychiatry Research. 157 (1–3): 303–306. doi:10.1016/j.psychres.2007.07.007. PMID17959254. S2CID10610680.
Halpern JH, Lerner AG, Passie T (2018). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Current Topics in Behavioral Neurosciences. 36: 333–360. doi:10.1007/7854_2016_457. ISBN978-3-662-55878-2. PMID27822679.
Majić T, Schmidt TT, Hermle L (2016). "Flashbacks und anhaltende Wahrnehmungsstörungen nach Einnahme von serotonergen Halluzinogenen". Handbuch Psychoaktive Substanzen [Flashbacks and persistent perceptual disturbances after ingestion of serotonergic hallucinogens] (in German). pp. 1–13. doi:10.1007/978-3-642-55214-4_63-1. ISBN978-3-642-55214-4.
Bogenschutz MP, Ross S (2016). "Therapeutic Applications of Classic Hallucinogens". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 361–391. doi:10.1007/7854_2016_464. ISBN978-3-662-55878-2. PMID28512684.
Mintzer MZ, Stoller KB, Griffiths RR (November 1999). "A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users". Psychopharmacology. 147 (2): 200–209. doi:10.1007/s002130051161. PMID10591888. S2CID35666163.
Garratt JC, Alreja M, Aghajanian GK (February 1993). "LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons". Synapse. 13 (2): 123–134. doi:10.1002/syn.890130205. PMID8446921. S2CID9496153.
Subramanian N, Doran M (March 2014). "Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report". Irish Journal of Psychological Medicine. 31 (1): 47–49. doi:10.1017/ipm.2013.59. PMID30189471. S2CID52170294.
Abraham HD, Mamen A (June 1996). "LSD-like panic from risperidone in post-LSD visual disorder". Journal of Clinical Psychopharmacology. 16 (3): 238–241. doi:10.1097/00004714-199606000-00008. PMID8784656.
Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A (January 2000). "LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study". International Clinical Psychopharmacology. 15 (1): 35–37. doi:10.1097/00004850-200015010-00005. PMID10836284. S2CID10871755.
Lerner AG, Gelkopf M, Skladman I, Rudinski D, Nachshon H, Bleich A (March 2003). "Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features". International Clinical Psychopharmacology. 18 (2): 101–105. doi:10.1097/00004850-200303000-00007. PMID12598822. S2CID24924089.
Matefy RE (April 1973). "Behavior therapy to extinguish spontaneous recurrences of LSD effects: a case study". The Journal of Nervous and Mental Disease. 156 (4): 226–231. doi:10.1097/00005053-197304000-00002. PMID4708882. S2CID9341528., Spevack M, Pihl R, Rowan T (April 1973). "Behavior therapies in the treatment of drug abuse: Some case studies". The Psychological Record. 23 (2): 179–184. doi:10.1007/BF03394152. S2CID149221411.
Hunter EC, Baker D, Phillips ML, Sierra M, David AS (September 2005). "Cognitive-behaviour therapy for depersonalisation disorder: an open study". Behaviour Research and Therapy. 43 (9): 1121–1130. doi:10.1016/j.brat.2004.08.003. PMID16005701.
Hunter EC, Phillips ML, Chalder T, Sierra M, David AS (December 2003). "Depersonalisation disorder: a cognitive-behavioural conceptualisation". Behaviour Research and Therapy. 41 (12): 1451–1467. doi:10.1016/s0005-7967(03)00066-4. PMID14583413.
Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (March 2011). "Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire". Drug and Alcohol Dependence. 114 (1): 61–67. doi:10.1016/j.drugalcdep.2010.09.006. PMID21035275.
Zobor D, Strasser T, Zobor G, Schober F, Messias A, Strauss O, et al. (April 2015). "Ophthalmological assessment of cannabis-induced persisting perception disorder: is there a direct retinal effect?". Documenta Ophthalmologica. Advances in Ophthalmology. 130 (2): 121–130. doi:10.1007/s10633-015-9481-2. PMID25612939. S2CID9684212.
Halpern JH, Lerner AG, Passie T (2016). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 333–360. doi:10.1007/7854_2016_457. ISBN978-3-662-55878-2. PMID27822679.
Halpern JH, Pope HG (March 2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–119. doi:10.1016/s0376-8716(02)00306-x. PMID12609692.
Sandison RA, Spencer AM, Whitelaw JD (April 1954). "The therapeutic value of lysergic acid diethylamide in mental illness". The Journal of Mental Science. 100 (419): 491–507. doi:10.1192/bjp.100.419.491. PMID13175011.
Robbins E, Frosch WA, Stern M (September 1967). "Further observations on untoward reactions to LSD". The American Journal of Psychiatry. 124 (3): 393–395. doi:10.1176/ajp.124.3.393. PMID6066637.
Horowitz MJ (October 1969). "Flashbacks: recurrent intrusive images after the use of LSD". The American Journal of Psychiatry. 126 (4): 565–569. doi:10.1176/ajp.126.4.565. PMID5806803.
Passie T, Schneider U, Borsutzky M, Breyer R, Emrich HM, Bandelow B, Schmid-Ott G (2013). "Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm". Psychology, Health & Medicine. 18 (3): 363–374. doi:10.1080/13548506.2012.722649. PMID23186162. S2CID39115198.
Simeon D, Kozin DS, Segal K, Lerch B, Dujour R, Giesbrecht T (January 2008). "De-constructing depersonalization: further evidence for symptom clusters". Psychiatry Research. 157 (1–3): 303–306. doi:10.1016/j.psychres.2007.07.007. PMID17959254. S2CID10610680.
Halpern JH, Lerner AG, Passie T (2018). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Current Topics in Behavioral Neurosciences. 36: 333–360. doi:10.1007/7854_2016_457. ISBN978-3-662-55878-2. PMID27822679.
Bogenschutz MP, Ross S (2016). "Therapeutic Applications of Classic Hallucinogens". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 361–391. doi:10.1007/7854_2016_464. ISBN978-3-662-55878-2. PMID28512684.
Mintzer MZ, Stoller KB, Griffiths RR (November 1999). "A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users". Psychopharmacology. 147 (2): 200–209. doi:10.1007/s002130051161. PMID10591888. S2CID35666163.
Garratt JC, Alreja M, Aghajanian GK (February 1993). "LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons". Synapse. 13 (2): 123–134. doi:10.1002/syn.890130205. PMID8446921. S2CID9496153.
Subramanian N, Doran M (March 2014). "Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report". Irish Journal of Psychological Medicine. 31 (1): 47–49. doi:10.1017/ipm.2013.59. PMID30189471. S2CID52170294.
Abraham HD, Mamen A (June 1996). "LSD-like panic from risperidone in post-LSD visual disorder". Journal of Clinical Psychopharmacology. 16 (3): 238–241. doi:10.1097/00004714-199606000-00008. PMID8784656.
Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A (January 2000). "LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study". International Clinical Psychopharmacology. 15 (1): 35–37. doi:10.1097/00004850-200015010-00005. PMID10836284. S2CID10871755.
Matefy RE (April 1973). "Behavior therapy to extinguish spontaneous recurrences of LSD effects: a case study". The Journal of Nervous and Mental Disease. 156 (4): 226–231. doi:10.1097/00005053-197304000-00002. PMID4708882. S2CID9341528., Spevack M, Pihl R, Rowan T (April 1973). "Behavior therapies in the treatment of drug abuse: Some case studies". The Psychological Record. 23 (2): 179–184. doi:10.1007/BF03394152. S2CID149221411.
Hunter EC, Baker D, Phillips ML, Sierra M, David AS (September 2005). "Cognitive-behaviour therapy for depersonalisation disorder: an open study". Behaviour Research and Therapy. 43 (9): 1121–1130. doi:10.1016/j.brat.2004.08.003. PMID16005701.
Hunter EC, Phillips ML, Chalder T, Sierra M, David AS (December 2003). "Depersonalisation disorder: a cognitive-behavioural conceptualisation". Behaviour Research and Therapy. 41 (12): 1451–1467. doi:10.1016/s0005-7967(03)00066-4. PMID14583413.
Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (March 2011). "Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire". Drug and Alcohol Dependence. 114 (1): 61–67. doi:10.1016/j.drugalcdep.2010.09.006. PMID21035275.
"Exhibit 1.3-4, DSM-5 Diagnostic Criteria for PTSD". Treatment Improvement Protocol (TIP) Series, No. 57. Center for Substance Abuse Treatment (US). Trauma-Informed Care in Behavioral Health Services. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 2014.
Zobor D, Strasser T, Zobor G, Schober F, Messias A, Strauss O, et al. (April 2015). "Ophthalmological assessment of cannabis-induced persisting perception disorder: is there a direct retinal effect?". Documenta Ophthalmologica. Advances in Ophthalmology. 130 (2): 121–130. doi:10.1007/s10633-015-9481-2. PMID25612939. S2CID9684212.
Passie T, Schneider U, Borsutzky M, Breyer R, Emrich HM, Bandelow B, Schmid-Ott G (2013). "Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm". Psychology, Health & Medicine. 18 (3): 363–374. doi:10.1080/13548506.2012.722649. PMID23186162. S2CID39115198.
Simeon D, Kozin DS, Segal K, Lerch B, Dujour R, Giesbrecht T (January 2008). "De-constructing depersonalization: further evidence for symptom clusters". Psychiatry Research. 157 (1–3): 303–306. doi:10.1016/j.psychres.2007.07.007. PMID17959254. S2CID10610680.
Garratt JC, Alreja M, Aghajanian GK (February 1993). "LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: intracellular studies in rat facial motoneurons". Synapse. 13 (2): 123–134. doi:10.1002/syn.890130205. PMID8446921. S2CID9496153.
Subramanian N, Doran M (March 2014). "Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report". Irish Journal of Psychological Medicine. 31 (1): 47–49. doi:10.1017/ipm.2013.59. PMID30189471. S2CID52170294.
Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A (January 2000). "LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study". International Clinical Psychopharmacology. 15 (1): 35–37. doi:10.1097/00004850-200015010-00005. PMID10836284. S2CID10871755.
Lerner AG, Gelkopf M, Skladman I, Rudinski D, Nachshon H, Bleich A (March 2003). "Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features". International Clinical Psychopharmacology. 18 (2): 101–105. doi:10.1097/00004850-200303000-00007. PMID12598822. S2CID24924089.
Matefy RE (April 1973). "Behavior therapy to extinguish spontaneous recurrences of LSD effects: a case study". The Journal of Nervous and Mental Disease. 156 (4): 226–231. doi:10.1097/00005053-197304000-00002. PMID4708882. S2CID9341528., Spevack M, Pihl R, Rowan T (April 1973). "Behavior therapies in the treatment of drug abuse: Some case studies". The Psychological Record. 23 (2): 179–184. doi:10.1007/BF03394152. S2CID149221411.
Fukunaga CJ, Cuddy C, Pizzolatto N, McConaughey M, Harrelson W, Monaghan M, Potts M, Arkapaw A, Hall A, Burnett TB (2016). True detective. Season 1, Season 1. OCLC964500128.[non-primary source needed]